r, only 2 of 21 (9%) subjects with Day 4 plasma concentrations ≥5 mcg/mL died. The therapeutic outcomes for the 134 subjects who received trial medication in this trial are presented in Table 9.
Table 9. Outcome of Treatment for PCP-positive Subjects (%) Enrolled in the Pentamidine Comparative Trial
16 HOW SUPPLIED/STORAGE AND HANDLING
MEPRON suspension (bright yellow, citrus-flavored) containing 750 mg atovaquone in 5 mL.
• Bottle of 210 mL with child-resistant cap (NDC 0173-0665-18). Store at 15° to 25°C (59° to 77°F). Do not freeze. Dispense in tight container as defined in USP.
• 5‑mL child‑resistant foil pouch ‑ unit dose pack of 42 (NDC 0173-0547-00). Store at 15° to 25°C (59° to 77°F). Do not freeze.
17 PATIENT COUNSELING INFORMATION
Administration Instructions
Instruct patients to:
• Ensure the prescribed dose of MEPRON suspension is taken as directed.
• Take their daily doses of MEPRON suspension with food, as food will significantly improve the absorption of the drug.
• Shake MEPRON suspension gently before use each time.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b426b6bf-f07e-4580-97ae-dfca1ddf5b8f |
